Engineered virus-like particles evolve for superior gene delivery efficiency

Researchers developed a barcoded directed evolution system for engineered virus-like particles (eVLPs), creating a fifth-generation (v5) eVLP with enhanced production, transduction, and gene-editing efficiency. This system could pave the way for improved gene delivery vehicles in therapeutic applications.

Johnson & Johnson seeks first drug approval for treatment of smoldering myeloma

This roundup of news from the ASH 2024 conference first appeared in STAT’s “ASH in 30” newsletter. To get future editions, sign up here. Welcome back,

December 9, 2024

Advanced melanoma survival rates improve significantly from 2013 to 2019, Dutch study finds

The change in overall survival (OS) among advanced melanoma patients diagnosed between 2013 and 2021.

February 14, 2024

Cerebellar inhibitory interneurons essential for fear memory, study finds

An LSU Health New Orleans research study led by Siqiong June Liu, PhD, Professor of Cell Biology and Anatomy, has found that cerebellar inhibitory interneurons

September 13, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.